Different effects of lipolytic hormones and phosphodiesterase inhibitors on cyclic 3',5'-AMP levels in isolated fat cells.
D000273:Adipose Tissue / Q000378:metabolism*; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000818:Animals; D000242:Cyclic AMP / Q000378:metabolism*; D004357:Drug Synergism; D005934:Glucagon / Q000494:pharmacology; D005990:Glycerol / Q000378:metabolism; D006728:Hormones / Q000494:pharmacology*; D007545:Isoproterenol / Q000494:pharmacology; D050356:Lipid Metabolism; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology; D010208:Papaverine / Q000494:pharmacology*; D010646:Phentolamine / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors; D011485:Protein Binding; D051381:Rats; D012710:Serum Albumin, Bovine; D013806:Theophylline / Q000494:pharmacology*; D014316:Tritium
D006728:Hormones; D010726:Phosphodiesterase Inhibitors; D014316:Tritium; D012710:Serum Albumin, Bovine; D000324:Adrenocorticotropic Hormone; D005934:Glucagon; D013806:Theophylline; D010208:Papaverine; D000242:Cyclic AMP; D007545:Isoproterenol; D005990:Glycerol; D009638:Norepinephrine; D010646:Phentolamine